PCA3 PREDICTS PROSTATE BIOPSY OUTCOME IN MEN RECEIVING DUTASTERIDE: RESULTS FROM THE DUTASTERIDE REDUCE TRIAL

被引：0
|
作者：
Andriole, G. [1 ]
Aubin, S. M. J. [2 ]
Reid, J. [2 ]
Samo, M. J. [2 ]
Blase, A. [2 ]
Aussie, J. [2 ]
Rittenhouse, H. [2 ]
Roger, R. [3 ]
Groskopf, J. [2 ,3 ]
机构：
[1] Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA
[2] Gen Probe Inc, Dept Oncol, San Diego, CA USA
[3] GlaxoSmithKline Inc, Oncol Clin Dev & Med Affairs, Res Triangle Pk, NC USA
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(10)60955-4
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：306 / 306
页数：1
相关论文
共 50 条
  • [21] BENEFITS AND HARMS OF DUTASTERIDE FOR PROSTATE CANCER IN THE RE-BIOPSY POPULATION FOR YEARS 1-2: A RE-ANALYSIS OF REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL
    Mir, Maria Carmen
    Li, Jianbo
    Kattan, Michael
    Jones, J. S.
    Stephenson, Andrew
    [J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E817 - E817
  • [22] Utility of PCA3 Urine Assay in Japanese Men Undergoing Prostate Biopsy
    Ochiai, A.
    Okihara, K.
    Kamoi, K.
    Shimazui, T.
    Oikawa, T.
    Tomita, K.
    Murayama, S.
    Umekawa, T.
    Uemura, H.
    Miki, T.
    [J]. UROLOGY, 2012, 80 (03) : S102 - S103
  • [23] COST-EFFECTIVENESS OF CHEMOPREVENTION WITH DUTASTERIDE BASED ON RESULTS FROM THE REDUCE CLINICAL TRIAL
    Earnshaw, S. R.
    McDade, C. L.
    Black, L.
    Kattan, M. W.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A271 - A271
  • [24] Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial
    Andriole, G
    Bostwick, D
    Brawley, O
    Gomella, L
    Tindall, D
    Breed, S
    Somerville, M
    Rittmaster, R
    [J]. JOURNAL OF UROLOGY, 2004, 172 (04): : 1314 - 1317
  • [25] The value of the PCA3 score in guiding prostate biopsy decision in men with a prior negative biopsy
    Haese, A.
    De La Taille, A.
    Van Poppel, H.
    Marberger, M.
    Stenzl, A.
    Mulders, P.
    Huland, H.
    Abbou, C. C.
    Joniau, S.
    Remzi, M.
    Tinzi, M.
    Feyerabend, S.
    Stillebroer, A.
    Van, Gils M.
    Schalken, J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 142 - 142
  • [26] Additional value of PCA3 density to predict initial prostate biopsy outcome
    Ruffion, A.
    Perrin, P.
    Devonec, M.
    Champetier, D.
    Decaussin, M.
    Paparel, P.
    Vlaeminck-Guillem, V.
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (04) : 917 - 923
  • [27] Additional value of PCA3 density to predict initial prostate biopsy outcome
    A. Ruffion
    P. Perrin
    M. Devonec
    D. Champetier
    M. Decaussin
    P. Paparel
    V. Vlaeminck-Guillem
    [J]. World Journal of Urology, 2014, 32 : 917 - 923
  • [28] CAN PROSTATE CANCER GENE 3 (PCA3) PREDICT INITIAL BIOPSY OUTCOME?
    de la Taille, Alexandre
    Irani, Jacques
    de Reijke, Theo M.
    Haese, Alexander
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 655 - 655
  • [29] PROSTATE BIOPSY: PATHOLOGICAL PATTERNS IN MEN WITH PROSTATE CANCER GENE 3 (PCA3) SCORE FLUCTUATIONS
    De Luca, Stefano
    Passera, Roberto
    Bollito, Enrico
    Cappia, Susanna
    Amparore, Daniele
    Cattaneo, Giovanni
    Manfredi, Matteo
    Mele, Fabrizio
    Bertolo, Riccardo
    Porpiglia, Francesco
    [J]. ANTICANCER RESEARCH, 2015, 35 (06) : 3723 - 3723
  • [30] CLINICAL UTILITY OF PCA3 URINE ASSAY IN JAPANESE MEN UNDERGOING PROSTATE BIOPSY
    Ochiai, Atsushi
    Okihara, Koji
    Kamoi, Kazumi
    Oikawa, Takehiro
    Shimazui, Toru
    Murayama, Shinichiro
    Tomita, Kyoichi
    Umekawa, Tohru
    Uemura, Hirotsugu
    Miki, Tsuneharu
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E915 - E915
12345